Biotech2k
Biotech Investor, AI-Driven Drug Discovery
Lemonade looks good but not good enough after a lofty price and high expectations into earnings, so it needs to get cheaper before it is worth buying. In-force premium grew 32% and revenue 79% as it approaches positive cash flow by the end of 2026; the low $40s or $30s would be the level to buy more. x.com x.com
Lemonade looks a bit expensive, with fair value around $60 to $70. The business itself is strong: it is growing over 30%, its reduced use of reinsurance has helped profitability, and it is expanding across property and casualty insurance with renters and pet as key lines. Its machine learning approach to analyzing and lowering risk should revolutionize the industry, and Lemonade is leading that change. x.com
Lemonade is reducing transparency on a key indicator of whether it can scale efficiently. Earnings reports once showed in-force premium versus opex, then switched to premium versus employee count, presumably as opex rose, and now show premium alone. Investors are tiring of waiting for EBITDA profitability, and the missing comparative metrics give less insight into how Lemonade gets there. The stock had run ahead into earnings, so a reset was due without a blowout. x.com x.com
Lemonade will likely fall back below $60 again, as it usually does, because it does not expect to be profitable until late 2027–2028, which keeps the stock volatile for a while. x.com
Lemonade's business thesis has not broken; the stock is falling on normal high-beta behavior, not fundamentals. With beta over two, high short interest and no profits yet, it moves sharply with risk appetite. Co-founder Daniel Schreiber's share sales are normal for a founder with concentrated wealth, though their framing was tone deaf, and stock pay is needed to hire engineers against Google and Meta. Long-term holders should watch in-force premium growth, loss ratio and operating leverage. … Show more
Lemonade's profitability problem outweighs its impressive growth. Revenue rose from $23 million in 2018 to $975 million over the last 12 months, a 65% CAGR, and members nearly tripled since 2021. Yet the capital-light insurtech still guides to negative 2026 EBITDA, below its initial expectations, and after 11 years is not close to positive EBITDA. Management has been less transparent about cutting costs. Solving profitability could make it a home run; Root's management is preferred. x.com x.com … Show more
Lemonade looks expensive once valued as what it is, an insurance company. Replying to @javierluraschi's post on the stock, any price above 1x revenue is expensive for an insurer. x.com
Lemonade could justify a $30-40B valuation by 2030 if it pairs growth with AI-driven margins, though this is a framework, not a price target. Compounding in-force premium 35-40% a year, led by Car and multi-product customers, could reach about $6B and $5.25B revenue; at a 20% EBITDA margin, 6-8x sales means $31.5-42B. In Q2 premium grew 33% and revenue 79% while headcount rose only about 5%. It must still control loss ratios and turn EBITDA consistently positive. x.com
Root looks cheap at about 7x earnings while buying back shares, with proven fully loaded economics. Even after $25.3 million of sales and marketing and $32 million of partner acquisition costs, it earned $25 million of GAAP profit with a 92.1% combined ratio. Lemonade grows much faster and may have more upside if retention and cross-sell deliver, but its case rests on modeled lifetime value and its shareholders keep getting diluted. Root's premium volume is roughly flat to down. x.com x.com … Show more
Lemonade's cash burn makes its promotion by paid influencers on X suspect. Its shares are down 38% year to date, alongside other heavily promoted stocks. x.com
Lemonade's share-price drop after a great second quarter is a wild overreaction. Per its Q2 2026 results, in-force premium rose 32.4% to $1.43 billion and revenue grew 79% to $294 million, the 11th straight quarter of accelerating growth, with over 3.3 million customers. x.com x.com
Lemonade is overvalued because AI is not a material or unique value driver in insurance, since every insurer uses AI and keeps improving it. It should trade at an insurance valuation of about 1.5-2.5x book value, roughly $30. An insurance CEO also called the company a joke and way overvalued. x.com x.com
